A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
All CHO cell lines are deficient in proline synthesis. Also, CHO cells do not express the epidermal growth factor receptor (EGFR), which makes them ideal in the investigation of various EGFR mutations. Furthermore, Chinese hamster ovary cells are able to produce proteins with complex glycosylations, post-translational modifications (PTMs) similar to those produced in humans. They are easily growable in large-scale cultures and have great viability, which is why they are ideal for GMP protein production. Also, CHO cells are tolerant to variations in parameters, be it oxygen levels, pH-value, temperature or cell density. Having a very low chromosome number (2n=22) for a mammal, the Chinese hamster is also a good model for radiation cytogenetics and tissue culture. Being the first cell line to be used for recombinant pharmaceutical production, regulatory concerns were raised with respect to Endogenous Retroviral Sequences (ERS). CHO cells contain about 1000 of these sequences and some of them are able to direct the synthesis of Intracisternal A-type particles and C-type particles. Also, low expression of reverse transcriptase was observed. However the majority of ERS are defective (stop codons in all reading frames) and contain large deletions of a putative retroviral genome.
146C → 147N + e− + νe By emitting a beta particle (an electron, e−) and an electron antineutrino (νe), one of the neutrons in the 14C nucleus changes to a proton and the 14C nucleus reverts to the stable (non-radioactive) isotope 14N.
== Reviews == Popp, Prank D. (1975). "The Chemistry of Isatin". Advances in Heterocyclic Chemistry Volume 18. Vol. 18. pp. 1–58. doi:10.1016/S0065-2725(08)60127-0. ISBN 978-0-12-020618-6. Silva, Joaquim F. M. da; Garden, Simon J.; Pinto, Angelo C. (June 2001). "The chemistry of isatins: a review from 1975 to 1999". Journal of the Brazilian Chemical Society. 12 (3): 273–324. doi:10.1590/S0103-50532001000300002. Mesropyan, E. G.; Avetisyan, A. A. (2009). "New isatin derivatives". Russian Journal of Organic Chemistry. 45 (11): 1583. doi:10.1134/S1070428009110013. S2CID 97341279. Varun, Varun; Sonam, Sonam; Kakkar, Rita (2019). "Isatin and its derivatives: a survey of recent syntheses, reactions, and applications". MedChemComm. 10 (3): 351–368. doi:10.1039/C8MD00585K. PMC 6438150. PMID 30996856.
In 2017, Burger King made a commitment they said would "require chicken suppliers to breed only higher-welfare strains of chickens, reduce the stocking density of the birds, improve light levels and litter quality inside barns, and use controlled atmosphere stunning to render the birds unconscious before slaughter, dramatically improving slaughter methods and the birds' living conditions;" however, a 2023 report from Compassion in World Farming, an animal advocacy organization, said that Burger King had not reported their progress in complying with the commitment, raising fears among animal advocates that the commitment was not being met. Burger King has been praised by animal advocates for the introduction of a Whopper made with a plant-based meat alternative from Impossible Foods and for the introduction of vegan menu items like the "Vegan Royale" in the UK. Burger King UK has pledged to offer a 50% meat-free menu by 2030.
Sources: en.wikipedia.org
=== Nonmedical use === Dexamethasone is given to prostituted Bangladeshi children, causing weight gain aimed at making them appear older and healthier to customers and police. Dexamethasone and most glucocorticoids are banned by sporting bodies including the World Anti-Doping Agency.
Potter (1842), officer during the American Civil War Augustus van Horne Ellis* (1844), Civil War general William Cutting* (1851), lawyer and soldier Henry Eugene Davies (1857), Civil War general William McNeill Whistler* (1857), Confederate soldier and surgeon, brother of James Abbott McNeill Whistler Alfred Thayer Mahan* (1858), president, U.S. Naval War College and author of The Influence of Sea Power Upon History William Jay (1859), soldier and lawyer, 40th president of the Saint Nicholas Society of the City of New York and great-grandson of first U.S. chief justice John Jay Alister Greene (1875), soldier and leader during the Gilded Age Duncan Elliot (1884), soldier and banker Hamilton Fish II (1895), first American killed in the Spanish–American War Ulysses S. Grant III* (1902), grandson of Ulysses S. Grant, entered with the class of 1902 but transferred to United States Military Academy Donald Armstrong (1909), brigadier general and commandant of the Army Industrial College John H. Hilldring* (1916), U.S. major general and former assistant secretary of state for occupied areas Melvin Krulewitch (1916), U.S. major general and president of the New York State Athletic Commission John F. "Jack" Hasey* (1940), American captain in the French Foreign Legion; recipient of the Order of Liberation
=== Wound healing and tissue repair === Even though PDRN's positive effects on wound healing and tissue repair were initially observed only in ephithelial tissue, it has also shown these effects across multiple tissue models. For instance, studies focused in wound closure in diabetic foot ulcers showed that PDRN can significantly reduce the time compared to placebo. The use of PDRN for wound treatment in clinical trials is considered cost-effective since it reduces hospital stays and the need for additional treatments. Moreover, PDRN showed significant improvement of mucosal healing, reduction of tissue injury and promotion of restoration of intestinal structure and function in a murine colitis model. However, one of the most common applications of this molecule in Asia is as a dematological biostumulator, because of its positive effects on the skin after abrasive procedures like laser or microneedling.
Sources: en.wikipedia.org
== Distribution and habitat == This species is found in parts of central and western Africa, in Burundi, Cameroon, Central African Republic, Democratic Republic of Congo, Republic of Congo, Equatorial Guinea, Gabon, Rwanda, and the province of Cabinda in Angola, as well as along the Burundian, Tanzanian and Zambian shores of Lake Tanganyika. It is largely an aquatic species and rarely is found far away from water. It can be found along lakes and rivers in forested and well-wooded savanna terrain where cover is sufficient, most commonly along lowland forested, bushy or wooded banks of lakes, rivers, and streams.
Japanese scientists from the Japan Aerospace Exploration Agency (JAXA) have discovered a huge cave on the moon with their Kaguya lunar probe, which could offer astronauts protection from dangerous radiation during future lunar landings, especially during the planned stopover of a Mars mission. As part of a human mission to Mars, astronauts must be protected from cosmic radiation. During Curiosity's mission to Mars, a Radiation Assessment Detector (RAD) was used to measure radiation exposure. The radiation exposure of 1.8 millisieverts per day was mainly due to the constant presence of high-energy galactic particle radiation. In contrast, radiation from the sun accounted for only about three to five percent of the radiation levels measured during Curiosity's flight to Mars. On the way to Mars, the RAD instrument detected a total of five major radiation events caused by solar flares. To protect the astronauts, a plasma bubble will surround the spacecraft as an energy shield and its magnetic field will protect the crew from cosmic radiation. This would eliminate the need for conventional radiation shields, which are several centimeters thick and correspondingly heavy. In the Space Radiation Superconducting Shield (SR2S) project, which was completed in December 2015, magnesium diboride was found to be a suitable material for generating a suitable force field.
Although HVEC ceased accelerator production in 1981, many of its machines remain active in nuclear physics research. Several have operated continuously for more than 50 years. Beyond AMS, active accelerators are used for nuclear astrophysics (studying neutron-induced reactions relevant to stellar nucleosynthesis), ion beam analysis, radiation effects testing, and ion-atom collision physics. Four remain at U.S. national laboratories: Argonne, Brookhaven, Lawrence Livermore, and Sandia. High Voltage Engineering Europa, the former Dutch subsidiary, continues manufacturing electrostatic accelerators for research and industrial applications.
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication. It was approved for medical use in the European Union in October 2005, and in the United States in September 2006. It is available as a generic medication.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.